Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)
A. Bapsi Chakravarthy(Vanderbilt University Medical Center), Al B. Benson(Northwestern University), Patrick J. Flynn(American Society of Clinical Oncology), Joel E. Tepper(University of North Carolina at Chapel Hill), James D. Brierley(University of Toronto), Nicholas J. Petrelli(Christiana Care Health System), Peter J. O’Dwyer(University of Pennsylvania), Elin R. Sigurdson(Fox Chase Cancer Center), Mary F. Mulcahy(Northwestern University), Fengmin Zhao(Dana-Farber Cancer Institute), David Cella(Northwestern University), Roger Santala, John R. Weis(University of Utah), Neal J. Meropol(Flatiron Health (United States)), Robert B. Diasio(Mayo Clinic), Frank A. Sinicrope(Mayo Clinic in Arizona), Paul J. Catalano(Computational Physics (United States)), Cynthia G. Leichman(NYU Langone Health), C. Cripps(Canadian Partnership Against Cancer), Stanley R. Hamilton(City of Hope), Lynne I. Wagner(University of North Carolina at Chapel Hill), Bruce J. Giantonio(Northwestern University), Edith P. Mitchell(Thomas Jefferson University Hospital), Timothy E. O’Brien(Case Western Reserve University), James N. Atkins(Southeastern Medical Oncology Center), Robert B. Catalano, Rashid Awan(UPMC Hillman Cancer Center), Jeffrey A. Sloan(Mayo Clinic), Daniel G. Haller(University of Pennsylvania)
Cited by 21
Related Papers
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
|Journal of Clinical Epidemiology|2010|5.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k